Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Piotroski F-Score: 7 (As of Jun. 30, 2026) — 17% Above Median


SHSE:688336 Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
85 GF Score
Price ¥53.05
GF Value ¥66.54
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Sunshine Guojian Pharmaceutical (Shanghai) Co Piotroski F-Score?

Sunshine Guojian Pharmaceutical (Shanghai) Co SHSE:688336 -0.09% 85 Piotroski F-Score is 7 as of Jun. 30, 2026, which is 17% above its 10-year median of 6.00. GuruFocus rates SHSE:688336 with a GF Score™ of 85/100 and a GF Value™ of ¥66.54 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,339 Biotechnology companies, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks better than 96.94% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sunshine Guojian Pharmaceutical (Shanghai) Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score or its related term are showing as below:

SHSE:688336' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Sunshine Guojian Pharmaceutical (Shanghai) Co was 9. The lowest was 3. And the median was 6.

Sunshine Guojian Pharmaceutical (Shanghai) Co  (SHSE:688336) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Sunshine Guojian Pharmaceutical (Shanghai) Co Piotroski F-Score Related Terms


Sunshine Guojian Pharmaceutical (Shanghai) Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunshine Guojian Pharmaceutical (Shanghai) Co Piotroski F-Score Chart

Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 6.00 7.00 7.00 9.00

Sunshine Guojian Pharmaceutical (Shanghai) Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 5.00 9.00 7.00

SHSE:688336 vs VRTX, REGN, ALNY: Piotroski F-Score Comparison

For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sunshine Guojian Pharmaceutical (Shanghai) Co Piotroski F-Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score falls into.


SHSE:688336
85GF Score
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd SHSE:688336
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 87.366 + 208.538 + 2500.444 + 178.118 = ¥2,974 Mil.
Cash Flow from Operations was 89.721 + 2625.508 + 230.211 + -154.666 = ¥2,791 Mil.
Revenue was 330.894 + 473.983 + 3083.122 + 431.234 = ¥4,319 Mil.
Gross Profit was 214.586 + 406.947 + 3008.535 + 348.043 = ¥3,978 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(6041.855 + 6012.592 + 8811.099 + 8957.374 + 8948.305) / 5 = ¥7754.245 Mil.
Total Assets at the begining of this year (Mar25) was ¥6,042 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Total Current Assets was ¥6,092 Mil.
Total Current Liabilities was ¥277 Mil.
Net Income was 38.391 + 103.538 + 471.53 + 102.956 = ¥716 Mil.

Revenue was 329.725 + 342.785 + 254.164 + 311.119 = ¥1,238 Mil.
Gross Profit was 231.79 + 270.604 + 181.115 + 236.099 = ¥920 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(5384.501 + 5397.427 + 5917.949 + 5965.027 + 6041.855) / 5 = ¥5741.3518 Mil.
Total Assets at the begining of last year (Mar24) was ¥5,385 Mil.
Long-Term Debt & Capital Lease Obligation was ¥0 Mil.
Total Current Assets was ¥3,040 Mil.
Total Current Liabilities was ¥297 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sunshine Guojian Pharmaceutical (Shanghai) Co's current Net Income (TTM) was 2,974. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Sunshine Guojian Pharmaceutical (Shanghai) Co's current Cash Flow from Operations (TTM) was 2,791. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=2974.466/6041.855
=0.49231006

ROA (Last Year)=Net Income/Total Assets (Mar24)
=716.415/5384.501
=0.13305133

Sunshine Guojian Pharmaceutical (Shanghai) Co's return on assets of this year was 0.49231006. Sunshine Guojian Pharmaceutical (Shanghai) Co's return on assets of last year was 0.13305133. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Sunshine Guojian Pharmaceutical (Shanghai) Co's current Net Income (TTM) was 2,974. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Cash Flow from Operations (TTM) was 2,791. ==> 2,791 <= 2,974 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=0/7754.245
=0

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=0/5741.3518
=0

Sunshine Guojian Pharmaceutical (Shanghai) Co's gearing of this year was 0. Sunshine Guojian Pharmaceutical (Shanghai) Co's gearing of last year was 0. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=6092.103/277.049
=21.98926183

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3039.525/297.456
=10.21840205

Sunshine Guojian Pharmaceutical (Shanghai) Co's current ratio of this year was 21.98926183. Sunshine Guojian Pharmaceutical (Shanghai) Co's current ratio of last year was 10.21840205. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Sunshine Guojian Pharmaceutical (Shanghai) Co's number of shares in issue this year was 890.591. Sunshine Guojian Pharmaceutical (Shanghai) Co's number of shares in issue last year was 878.154. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3978.111/4319.233
=0.92102255

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=919.608/1237.793
=0.74294167

Sunshine Guojian Pharmaceutical (Shanghai) Co's gross margin of this year was 0.92102255. Sunshine Guojian Pharmaceutical (Shanghai) Co's gross margin of last year was 0.74294167. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=4319.233/6041.855
=0.71488525

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=1237.793/5384.501
=0.22988073

Sunshine Guojian Pharmaceutical (Shanghai) Co's asset turnover of this year was 0.71488525. Sunshine Guojian Pharmaceutical (Shanghai) Co's asset turnover of last year was 0.22988073. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Sunshine Guojian Pharmaceutical (Shanghai) Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Piotroski F-Score of 7 as of Jun. 30, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. This is 17% above median its historical median of 6.00. Over the past decade, Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #41 out of 1339 companies in the Biotechnology industry, placing it in the top 3.1%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Piotroski F-Score of 7 is 17% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Biotechnology industry median Piotroski F-Score is 3.00. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 7 is 133.3% above this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #41 out of 1339 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 85/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Piotroski F-Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #41 out of 1339 companies for Piotroski F-Score. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the top 3% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 3.00. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 7 is 133.3% above this benchmark. Historically, Sunshine Guojian Pharmaceutical (Shanghai) Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 3.00, Sunshine Guojian Pharmaceutical (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Biotechnology company?
The median Piotroski F-Score among Biotechnology companies is 3.00, based on 1,339 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Piotroski F-Score of 7 is 133.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. For the Biotechnology industry, the median Piotroski F-Score is 3.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Piotroski F-Score is 7, which is 17% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥66.54, compared to a current price of ¥53.05 — trading 20.3% below its estimated fair value. The current Piotroski F-Score is 7, which is 17% above median its 10-year median of 6.00 and 133.3% above the Biotechnology industry median of 3.00. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 85/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Piotroski F-Score is 7 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?

Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued. The current stock price of ¥53.05 is trading 20.3% below its estimated GF Value™ of ¥66.54. GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.

Key valuation signals for SHSE:688336:

  • Piotroski F-Score: 7 (17% above median its 10-year median of 6.00)
  • GF Value™: ¥66.54 vs. price of ¥53.05 (20.3% below fair value)
  • GF Score™: 85/100 with 3 warning signs
  • Industry Position: 133.3% above the Biotechnology median (#41 of 1339)

No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sunshine Guojian Pharmaceutical (Shanghai) Co Business Description

Address No.399 Libing Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, CHN, 201203
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
85GF Score

Get the complete analysis for SHSE:688336

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥53.05
Price
¥66.54
GF Value